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Abstract: Objective.This study was designedto determine clinical
outcomes with caspofungin in patients with proven or probable
invasive fungalinfection (IFI) after a solidorgantransplant (SOT)
procedure.
Methods. Inthis retrospective observational study, datawere collected
for a single episode of IFI in patientswith an SOT betweenJanuary
2004 andJune 2007. Responsewas determinedby the investigator as
favorable(completeorpartial)or unfavorable(stablediseaseorfailure)
at the end of caspofungin therapy (EOCT).The primary e¡ectiveness
populationwasthe proportionof patientswho received  5 doses of
caspofungin (modi¢ed all-patients-treatedpopulation). Safety was
assessed for patientswho received  1dose ofcaspofungin.
Results. Atotal 81of patientsfrom13sitesin China, Germany,Italy, and
the United Kingdom were enrolled, including 49 (60%) liver, 22 (27%)
heart,5 (6%) lung, 2 (2%) kidney,2 (2%) liver and kidney, and1 (1%)
pancreas and kidney recipients. Candidiasiswas diagnosed in 64/81
patients (79%) and aspergillosis in 22/81patients (27%). Most patients
received caspofungin monotherapy (75%). Caspofunginwas given as
¢rst-linetherapy to 59 (73%) patients.The overall favorable response at
EOCTwas 87%(58/67; 95%con¢dence interval [CI]:76%,94%),with
favorable responsesin 88%(43/49; 95%CI:75%,95%) of patients
receivingcaspofungin monotherapy and 83%(15/18; 95%CI:59%,
96%) of patients receiving combination therapy with caspofungin
(modi¢ed all-patients-treated population). Response by type of SOT
was as follows: liver 87% (39/45), heart 93% (14/15), kidney100% (5/5),
and lung 50% (2/4). An overall survival rate (all-patients-treated) of
69%(56/81; 95%CI:59%,79%) was observed at 7 days post EOCT. No
serious drug-related adverse events were reported.
Conclusion.In this study, caspofungin was e¡ective and well tolerated
in the treatment of IFIs involving SOTrecipients.
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Fungal infections are a common cause of morbidity and
mortality in solid organ transplant (SOT) recipients. The
reportedincidenceoffungalinfectionsrangesfrom4^42%
in liver transplant recipients (1) and from 15^35% in
lung transplant recipients (2). Candida species are the
most common pathogens, accounting for approximately
43^80% of fungal infections following liver (1, 3), heart (4),
and lung transplantation (5). Aspergillus specieshavebeen
isolated from approximately 9^34% of patients with in-
vasive fungal infection (IFI) after liver transplantation (6)
and 20^50% after lung transplantation (5^7). Increased
mortality rates (20^90%) have been reported among SOT
recipientssu¡eringfromIFIscomparedwithSOTpatients
with no IFI (6, 8, 9).
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230RiskfactorsforCandidainfectionincludeahighintraop-
erative transfusion requirement as well as post-transplant
bacterial infection (1). Renal failure andthe need fordialy-
sis have been described as risk factors for early-onset Asp-
ergillus infection; risk factors in patients with late-onset
infections (43 months after transplantation) included
age, intensi¢ed immunosuppression due to factors such as
chronictransplantrejection,andpost-transplantrenalfail-
ure (10).While optimizing treatmentof IFI in SOTpatients
may decrease attributable mortality (6,11), limited data are
available from randomized clinical trials regarding which
treatmentsaremoste¡ectiveforSOTpatientswithIFI(12).
Currenttherapeutic options for invasive fungal disease in-
clude echinocandins, polyenes, and azoles (13^16).
C a s p o f u n g i ni sa ne c h i n o c a n d i na p p r o v e df o rt r e a t i n g
adult and pediatric patients with invasive candidiasis, as
empiricaltherapyinpresumedfungalinfectionsincluding
Candida or Aspergillus in febrile, neutropenic adult pa-
tients, and for treatment of invasive aspergillosis in adults
who are refractoryor intolerant to other antifungal agents.
Itismetabolizedindependentlyofcytochrome450andmay
therefore have fewer interactions with calcineurin inhibi-
tors(CNIs)suchascyclosporine or tacrolimus(17^19).This
retrospective observational study evaluated the e¡ective-
ness and safety of caspofungin as treatment for invasive
fungaldisease inpatientswhohad received an SOT.
Patients and methods
Thisretrospective,multicenterobservationalstudy wasde-
signed to evaluate clinical and safety outcomes in patients
with proven or probable invasive fungal disease treat-
ed with caspofungin following a SOT. The study was per-
formed at 13 transplant centers in China (n53), Germany
(n55), Italy (n54), and the United Kingdom (n51). Cen-
tral and local regulatory and Independent Ethics Commit-
tee approvals were obtained as required by each site or
country.
PatientswhoreceivedanSOTbetweenJanuary2004and
January2007andhadreceiv edcaspofunginfollowingSOT
for treatment of a proven or probable IFI were eligible for
inclusion. EORTC-MSG criteriawere used as aguide to as-
sesswhether IFIcaseswere provenor probable (20). Charts
were reviewed between July 2007 and December 2007. If
multiple transplant procedures took place, the procedure
closest in time to the onset of post-transplant IFI was con-
sidered. Patients who participated in Merck-sponsored
clinical studies for IFI during the hospitalization were ex-
cluded.Asthiswas a retrospectiveobservationalstudy,no
medicationwasprovidedtosites.Caspofunginwas admin-
istered according to clinician’sjudgmentandlocaldiagnos-
tic andtreatment pathways.
E¡ectiveness and safety assessments
Data for consecutive patient cases meeting the eligibility
criteria were entered at each site into this observational
study. Internet-based electronic case report forms were
used to collect patient data. Demographic characteristics,
medical history, caspofungin dosing regimen, other anti-
fungal drugs received, co-administered immunosuppres-
sive agents, and dose and duration of therapy were
recorded. Information was collected on co-morbidities and
predisposingriskfactors,i.e.,active malignancy,renalfail-
ure requiring dialysis, primary graft non-function, re-
transplantation, exposure to 43 antibiotics, recent use of
central venous catheter, current steroid dose (i.e., during
this hospitalization), current monoclonal antibody use for
immunosuppression (i.e., during this hospitalization),
hyperglycemia, neutropenia (absolute neutrophil count
o500cells/mL), recent parenteral nutrition (hyper-
alimentation), United Network for Organ Sharing (UNOS)
Class 1 (i.e., patients with a life expectancy of o7d a y s
withoutaliver transplantandwithfulminant[sudden]liv-
er failure,or withnewly transplantedlivernot functioning,
respectively [21]) clinical urgency of transplantation, pre-
transplantation fungal colonization, cytomegalovirus
(CMV) infection, long duration of transplant procedure
(45h), biliary construction using Roux loop, re-operation
(laparatomy) within 5 days after transplantation, need for
substantial (  40U) intraoperative transfusions, hepatic
iron overload, thrombocytopenia, fulminant hepatic fail-
ure, recent intensive care unit (ICU) stay (i.e., during this
hospitalization), and ambient/community-acquired expo-
sure (i.e., before hospitalization). Data on type of SOT, site
of IFI following transplantation, mycology, and severity of
illness measureswere also collected.
According to the pre-speci¢ed analysis plan, the pri-
mary e¡ectiveness population was based on a modi¢ed
all-patients-treatedpopulation,whichincludedallpatients
who received  5 doses of caspofungin for treatment of
IFI. Mycological information, if available, was collected
viachart reviewandincludedsite offungalinfection,type
of fungal infection, diagnostic tests usedto identify fungal
species,anddiagnosisoftheinfection.Aspartofthechart
review, no post hoc veri¢cation of mycological tests and no
resistancetestswere performed.The chart review involved
taking data as available in the charts.
Safety was assessed for the all-patients-treated popula-
tion,whichwasde¢nedasanypatientwhoreceivedatleast
1d o s eo fc a s p o f u n g i n .As u m m a r yo ft h en u m b e ra n dp e r -
centage of patients who had at least 1 drug-related adverse
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deathwas producedbycollecting drug-related clinical and
laboratory adverse events, drug^drug interactions, and
discontinuations ordeaths associatedwith drug-related ad-
verse events. Drug-related events referred to those events
consideredby theinvestigatoraspossibly,probably,orde¢-
nitely related to caspofungin therapy. All outcomes were
determined based on the judgment of the investigator.
De¢nitionsof response
The primary endpoint was the proportion of patients who
received  5 doses ofcaspofungin and had a favorable re-
sponse to treatment.Treatment response was determined
by the investigator as favorable (complete or partial) at the
end ofcaspofungintherapy (EOCT), or unfavorable (stable
disease or disease progression) at EOCT. In addition, sur-
vivalwas assessed at hospitaldischarge.
Completeresponsewasde¢nedasresolutionofallattrib-
utable clinical and radiological signs and symptoms of in-
vasive mycosis at EOCT;partialresponsewasde¢nedas a
substantial reduction of attributable clinical and radiologi-
cal pre-treatment signs and symptoms of invasive mycosis
at EOCT; stable disease was de¢ned as minimal or no re-
duction of attributable clinical and radiological signs and
symptoms of invasive mycosis at EOCT; and failure was
de¢ned as worsening of signs and symptoms of invasive
mycosis at EOCT. Response was determined based on the
treating physician’s clinical judgment. Minimal observa-
tionperiodwas 7 days after EOCT.
Statistical analysis
Patientcharacteristics,patientriskfactorsforinvasivefun-
gal disease, indication for caspofungin therapy, immuno-
suppressive therapy at onset of caspofungin therapy, and
proportion of favorable response by pathogen were
assessed overall, and by type of therapy (caspofungin
monotherapy and caspofungin combination therapy,
respectively) using descriptive statistics.
Results
Patient baseline characteristics
A total of 81 patients were included in this observational
study. Sixty-one patients (75%) were male. Patients had a
median of 2 medical comorbidities at study entry (mean
2.8; range 1^8); liver disease was the most common condi-
tion (52/81patients,64). SOTs included liver in 49 patients
( 6 0 % ) ,h e a r ti n2 2p a t i e n t s( 2 7 %) ,l u n gi n5p a t i e n t s( 6 % ) ,
kidney in 2 patients (2%), liver and kidney in 2 patients
(2%), and pancreas and kidney in 1patient (1%). At initia-
tion of caspofungin therapy, the median age was 54 years
(range 24^70; standard deviation [SD], 10.38), and the me-
dianweightwas68kg(range44^103kg;SD,12.95).Theme-
diandurationof transplantoperationwas 6.5h (SD,3.551).
Risk factors andimmunosuppression
Patientshadamedianof8riskfactorsforIFIatinitiationof
caspofungintherapy(Table1).Patientriskfactorsincluded
recentuse ofcentralvenouscatheter(90%),recentICUstay
(85%), current steroid dose (83%), duration of transplant
procedure 45h (70%), exposure to 43 antibiotics (53%),
andrecentparenteralnutrition(53%).Atthestartofcaspo-
fungintherapy,76/81patients(94%)werenon-neutropenic,
49/81 patients (61%) had mechanical ventilation, 29/81 pa-
tients (36%) had renal replacement therapy, and 16/81
(20%) had evidence of acute 14/16 (88%) or chronic 2/16
(13%) organ rejection.
Overall, 71/81 patients (88%) received immunosuppres-
sive therapy (Table 2). Corticosteroids were used by 65/81
patients (80%; mainly prednisolone [median dose 25mg/
day; mean 62.8; range 5^750; n528] and prednisone [me-
dian dose10mg/day; mean10; range 5^750; n513]).Tacro-
limus, administered to 54% of patients; mycophenolate
mofetil, administered to 27%; and cyclosporin A, adminis-
tered to 25% of patients, were among the most frequently
prescribed immunosuppressants. Compared with caspo-
fungin combination therapy, patients on caspofungin
monotherapy were numerically more likely to have a his-
toryof substantial intraoperative transfusions (prevalence
ratio [PR] 3.1, P50.02 [Fisher’s exact]), UNOS Class 1 (PR
2.3, P50.2), biliary Roux loop construction (PR 2.3,
P50.7), or clinical urgency of transplantation (PR 2.1,
P50.2), and were numerically less likely to have primary
graft non-function (PR 0.2, P50.1), ambient/community
acquired fungal infection (PR 0.3, P50.3), re-transplanta-
tion(PR0.4,P50.2), or active malignancy (PR 0.4, P50.2).
Descriptionof infection
Atotal of 66/81patients were treated for IFI during the ini-
tial phase following SOT; 15/81 patients (19%) had been
discharged from the hospital following transplant but be-
fore IFI. At least 1 culture was taken from sterile sites for
47/81patients (58.0%), with 21fromthelung. Culturesfrom
non-sterile sites were taken from 43/81 patients (53.1%), in
particularfromrespiratorysecretionsin34/43cases(79%).
Proven fungal infections were diagnosed in 38/81 patients
(46.9%), with 9/38 due to proven Aspergillus infection
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(13.2%) mixed infections, and1/38 (2.6%) due to a mold in-
f e c t i o ni nas u r g i c a lw o u n di na nA s i a np a t i e n tt h a tc o u l d
notbe speci¢ed further (Table 3).The site of infectionwas
t h el u n gi n5 0 / 8 1p a t i e n t s( 6 2 % ) ,m u l t i p l es i t e si n1 3 / 8 1p a -
tients (16%), blood in 6/81 (7%), sinus in 2/81 (3%), and in-
tra-abdominal infection in 6/81 (7%; organs a¥icted:
abdomen not further speci¢ed 3, kidney 1, liver/spleen 1,
and abscess not further speci¢ed 1). Four patients had
other sites of infection (5%).
Prioror adjuvant antifungal therapy
All patients were treated with caspofungin either as ¢rst-
line (n559) or second-line (n522) therapy. At the discre-
tionofthetreatingphysician,andbasedonlocaldiagnostic
and treatment pathways only, caspofungin was given as
monotherapy to 61 patients; the remaining 20 patients re-
ceived concomitant therapy with other antifungal agents.
Before initiation of caspofungin, 30 patients had been
treated with other antifungals. Of these, 10 had received
Patient risk factors for invasive fungal disease with at least 1 patient a¡ected
N (%)
Caspofungin monotherapy
1
N561
Combination therapy
N520
Overall
N581
Number of risk factors per patient
2 (median [mean; range; SD]) 8 [8.2; 4^18; 2.6] 8 [7.3; 2^15; 3.4] 8 [8.0; 2^18; 2.9]
Active malignancy 5 (8) 4 (20) 9 (11)
Renal failure requiring dialysis 25 (41) 5 (25) 30 (37)
Primary graft non-function 2 (3) 3 (15) 5 (6)
Re-transplantation 5 (8) 4 (20) 9 (11)
Exposure to 43 antibiotics 29 (48) 14 (70) 43 (53)
Recent use of central venous catheter 55 (90) 18 (90) 73 (90)
2
Current steroid dose
3 50 (82) 17 (85) 67 (83)
Current monoclonal antibody use for immunosuppression
3 21 (34) 4 (20) 25 (31)
Hyperglycemia 23 (28)
2 11 (55) 34 (42)
Neutropenia
4 4( 7) 0( 0) 4( 5)
Recent parenteral nutrition (hyperalimentation) 36 (59) 7 (35) 43 (53)
UNOS Class 1 14 (23) 2 (10) 16 (20)
Clinical urgency of transplantation 19 (31) 3 (15) 22 (27)
Pretransplantation fungal colonization 8 (13) 2 (10) 10 (12)
CMV infection 15 (25) 5 (25) 20 (25)
Long duration of transplant procedure (45h ) 4 7( 7 7) 1 0( 5 0) 5 7( 7 0)
Biliary construction using Roux loop 7 (12) 1 (5) 8 (10)
Re-operation (laparatomy) within 5 days after transplantation 11 (18) 5 (25) 16 (20)
Need for substantial ( 40U) intraoperative transfusions 28 (46) 3 (15) 31 (38)
Thrombocytopenia 15 (25) 7 (35) 22 (27)
Fulminant hepatic failure 5 (8) 1 (5) 6 (7)
Recent ICU stay
3 54 (89) 15 (75) 69 (85)
Ambiental/community acquired exposure (i.e.,before hospitalization) 2 (3) 2 (10) 4 (5)
Other 1 (1.6) 0 (0) 1 (1.2)
1Data for 1patient in the monotherapy group were missing except for the categories designated‘Other,’ ‘Biliary construction using Roux loop,’and‘CMV
infection.’
2At initiation of caspofungin therapy.
3During this hospitalization.
4ANCo500cells/mL.
SD, standard deviation; UNOS,United Network for Organ Sharing; CMV,cytomegalovirus; ANC, absolute neutrophil count; ICU,intensive careunit.
Table 1
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Transplant InfectiousDisease 2010: 12: 230^237 233prophylactic treatment (1 amphotericin B colloid disper-
sion, 6 £uconazole, 1 voriconazole, 2 itraconazole); 15 em-
piric therapy (2 liposomal amphotericin B, 3 voriconazole,
6 £uconazole, 1 amphotericin B colloid dispersion/
voriconazole, 1 itraconazole, 2 voriconazole/£uconazole
combination); and 5 de¢nite therapy (1 £uconazole, 1
amphotericin lipid complex, 1 £uconazole/voriconazole,
1 £uconazole/voriconazole/liposomal amphotericin B, 1
itraconazole/£uconazole). Reason for switching to or add-
ing caspofungin was immunosuppressive therapy in 10
patients; clinically refractory to ¢rst-line antifungal in 8;
microbiologically refractory to¢rst-line antifungalin 3; ne-
phrotoxicity in 2; sensitivity to caspofungin in 2; and un-
known in 5. Of the 20/67 patients who received
combination therapy, in addition to caspofungin, 10%
received voriconazole; 9% received amphotericin B or its
lipid formulations; and 1% received voriconazole and £u-
conazole.Treatment was initiated for proven fungal infec-
tion in 38/81 patients (47%) and probable fungal infection
in 43/81 patients (53%), respectively (Table 3). Following
caspofungin therapy, 15 (19%) patients received £ucona-
zole, 10 (12%) received voriconazole, 4 (5%) received am-
photericin B oritslipidformulations,and10(12%)received
other antifungals.
Clinicalresponse
Afavorable(completeorpartial)responseatEOCTwasob-
served in 58/67 patients (87%; 95%con¢dence interval [CI]
76%; 94%) inthe modi¢ed all-patients-treatedpopulation.
In the modi¢ed all-patients-treated population, 35/67 pa-
tients (52%) had a complete response, and 23/67 (34%)
had a partial response. A favorable response was seen in
67/81patients (83%; 95%CI 73%; 90%) inthe all-patients-
treated population. Favorable responses were also noted in
14/19 patientswithprobable or proven Aspergillusinfection
(74%), and in 59/66 patients with Candida infection (89%;
Table 4).
Safety
In the all-patients-treated population, 25/81 (30.9%) pa-
tients had died at the end of observation, i.e., hospital dis-
Immunosuppressive therapy at onset of caspofungin therapy
Caspofungin monotherapy Combination therapy
Overall (N581) Immunosuppressive therapy
1 With steroid (N547) Without steroid (N514) With steroid (N518) Without steroid (N52)
Any therapy 43 (91.5) 10 (71.4) 18 (100) 0 (0.0) 71 (87.7)
Tacrolimus 25 (53.2) 10 (71.4) 9 (50.0) 0 (0.0) 44 (54.3)
Cyclosporin A 12 (25.5) 0 (0.0) 8 (44.4) 0 (0.0) 20 (24.7)
Sirolimus 0 (0.0) 0 (0.0) 1 (5.6) 0 (0.0) 1 (1.2)
Mycophenolate mofetil 21 (44.7) 2 (14.3) 3 (16.7) 0 (0.0) 26 (32.1)
Azathioprine 1 (2.1) 0 (0.0) 1 (5.6) 0 (0.0) 2 (2.5)
Other 6 (12.7) 3 (21.4) 2 (11.1) 0 (0.0) 11 (13.6)
B a s i l i x i m a b 1( 2 . 1 ) 2( 1 4 . 3) 1( 5 . 5) 0( 0 . 0) 4( 4 . 9)
Muromonab-CD 3 0 (0.0) 0 (0.0) 1 (5.5) 0 (0.0) 1 (1.2)
Daclizumab 3 (6.4) 1 (7.1) 0 (0.0) 0 (0.0) 4 (4.9)
1Patients may have received 41immunosuppressive therapy.
Table 2
Indication for caspofungin therapy fungal infection
Caspofungin
monotherapy
N561
Combination
therapy
N520
Overall
N581
Proven fungalinfection (n538/81)
Aspergillosis 4 (14) 5 (56) 9 (24)
Candidiasis 22 (76) 1 (11) 23 (61)
Mixed
1 2( 7) 3( 3 3) 5( 1 3)
Other
2 1( 3) 0( 0) 1( 3)
Probable fungalinfection (n543/81)
Aspergillosis 5 (16) 2 (18) 7 (16)
Candidiasis 26 (81) 9 (82) 35 (81)
Mixed
1 1( 3) 0( 0) 1( 2)
1Mixed category indicates Aspergillus and Candida infection.
2Other category includes other mold infection.
Table 3
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fungal infection was the primary reason for death in 3/81
patients (3.7%). Other reasons for death were multi-organ
failure (n512, 14.8%); single organ failure (n54, 4.9%);
bacterial infection (n53, 3.7%); graft-versus-host disease
inapatientwithphotoskintypeVIwhohadreceivedaliver
transplant for cryptogenic cirrhosis, su¡ered from
neutropenia, and had received treatment with monoclonal
antibodies (n51, 1.2%); bronchopneumonia and acute
respiratory distress syndrome (n51, 1.2%); and di¡use
hemorrhage (n51, 1.2%). One patient in the caspofungin
monotherapy group experienced drug-related adverse
events (pyrexia and hyperbilirubinemia) as did 1 in the
combination therapy group (nausea). No serious drug-
related adverse events were reported. No patients required
discontinuation of caspofungin due to a drug-related ad-
verse event.Inthe modi¢edall-patients-treatedpopulation,
18/67 patients (26.9%) died at the end of observation,
a m o n gt h e s e6d u r i n gt h e¢ r s t7d a y sa f t e rc o m p l e t i o no f
caspofungintherapy.
Discussion
Invasive fungal disease has become an important cause of
death in SOTrecipients, particularly followinglung orliver
transplantation. Amphotericin B was the only drug avail-
able for these patients for years, thus amphotericin B and
its lipid formulationswere oftenusedto treatthese patients
despite the riskof hepatic failure (22) and renal impairment
(23), which can be exacerbated when combined with CNIs
(6). SOTrecipients may in factbe excluded from large trials
because of thepotentialconfoundingcomplicationsof man-
datory immunosuppressivetherapy. Drug interactionswith
CNIs are a major issue intransplant patients.The adventof
newer agents such as the echinocandins may represent a
therapeutic opportunity. Caspofungin is not associated
with major drug-to-drug interactions involving the cyto-
chrome 450 metabolism of CNIs (18).This factor was impor-
tant in the present study, where 9 patients were switched to
caspofungin from another antifungal agent owing to drug
interactions with immunosuppressive therapy. Most pa-
tients who were e¡ectively managed with caspofungin re-
ceived concomitant immunosuppressive agents. These
results are particularly relevant because current published
data on caspofungin in SOT patients have been mostly in
theformofanecdotalcase reports(24^26),reportsonsmall
patient groups (27), and salvage studies (19).
Inourstudy,Candidawasthemostcommoncauseoffungal
infection.Sites ofinfectionwere comparabletothose reported
in other studies (1, 9).We found a relatively higher number of
Candida and Aspergillus mixed infections compared with the
literature (6), although Fujishita et al. (28) reported 3 hemato-
oncological cases of pulmonary mycosis due to mixed Can-
didaandAspergillusinfectionin32patients(9.4%).Onepossi-
ble explanation for the higher number of mixed infections is
that many studies focus on eitherAspergillus or Candida spe-
cieswhile our studyevaluated all eligible SOTrecipients.
Caspofunginwas e¡ective as ¢rst- and second-line ther-
apy inthis group of patients with a favorable response rate
of 87% in SOT recipients with proven or probable IFI. It
was noteworthy that 89% of patients with proven or prob-
able invasive Candida infection and 74% of patients with
proven or probable Aspergillus infection responded to
caspofungin treatment, similar to results reporting that
caspofungin was an e¡ective treatment in invasive asper-
gillosis after SOT (29). Prophylaxis for spontaneousbacte-
rial peritonitis, fulminant hepatitis, retransplantation,
dialysis,andCMVviremiahavebeenidenti¢edasriskfac-
torsforinvasiveCandidainfectioninlivertransplantrecip-
ients (30). Favorable response rates in our patients
presenting these 5 risk factors were between 62.5% (re-
transplantation) and 85.7%(exposureto 43 antibiotics).
The overall mortality observed (31% at 7 days post
EOCT) was relatively high.This is most likelybecause the
patientsincluded inthis study were severely ill.The 24 pa-
tientswithAPACHEIIscoredatahadamedianscoreof23,
whereascoreof420isoftenusedtoindica tehighsev erity
Proportion of patients with favorable response by pathogen
Pathogen
Caspofunginmonotherapy
n/N (% [95% CI])
Combination therapy
n/N (% [95% CI])
Total
n/N (% [95% CI])
Aspergillus 7/9 (78 [40; 97]) 7/10 (70 [35; 93]) 14/19 (74[49; 91])
Candida albicans 24/26 (92 [75; 99]) 8/10 (80 [44; 98]) 32/36 (89 [74;97])
Non-albicansCandida 19/20 (95 [75; 100]) 4/5 (80 [28; 100]) 23/25 (92[74; 99])
Mixed Candida species 2/3 (67 [9; 99]) 2/2 (100 [16; 100]) 4/5 (80 [28; 100])
CI,con¢dence interval.
Table 4
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Transplant InfectiousDisease 2010: 12: 230^237 235of illness. Also, a large majorityof patients received immu-
nosuppressive therapy. The mean duration of transplant
operationof  7hindicatesmoredi⁄cultoperativeproce-
dures.
This study had several inherent limitations. As a retro-
spective observational study, there was no comparator
arm. Also, because of potential confounding due to imbal-
a n c e so fp r o g n o s t i cf a c t o r s ,n oc o n c l u s i o n ss h o u l db e
drawn regarding the outcome of caspofungin monothera-
pyrelativetotheoutcomeofcaspofungincombinationther-
apy. Results may have been a¡ected by the relatively low
numberof patientsinsome categories, andtherewas a rel-
atively brief follow-up period after the EOCT.
Nevertheless, in this retrospective observational study,
the clinical response rate of patientstreatedwith caspofun-
ginforIFIafterSOTwascomparabletoratesshowninran-
domizedtrials in non-SOTpatients.
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